| Huang |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
| Active, not recruiting | 2 | 15 | US | CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing | AstraZeneca | Primary Aldosteronism, Hyperaldosteronism | 10/24 | 10/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation |
|
|
| Active, not recruiting | 1/2 | 315 | Europe, Canada, Japan, US, RoW | Sunvozertinib, DZD9008 | Dizal Pharmaceuticals | Non-Small Cell Lung Cancer | 07/24 | 07/25 | | |
| Recruiting | 1 | 16 | RoW | ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Kidney Impairment | 04/24 | 05/24 | | |
NCT06752746: A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera |
|
|
| Recruiting | 1 | 108 | RoW | 9MW3011 | Mabwell (Shanghai) Bioscience Co., Ltd. | Polycythemia Vera | 08/25 | 06/26 | | |
NCT01522183: Atypical Hemolytic-Uremic Syndrome (aHUS) Registry |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, US, RoW | | Alexion Pharmaceuticals, Inc., Syneos Health | Atypical Hemolytic-Uremic Syndrome | 01/31 | 01/31 | | |
| Zhang, Yaojun |
| Recruiting | 1 | 9 | RoW | BST02 | BioSyngen Pte Ltd | Locally Advanced Liver Carcinoma | 07/25 | 12/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Xu, Chunrong |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| huang, fengjiao |
| No trials found |
